Pfizer/Coley Prep Phase III Study Of ProMune For First-Line Lung Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
ProMune Phase III lung cancer trial plans outlined in Coley's recent IPO prospectus filing. With licensee Pfizer funding ProMune for cancer applications, the bulk of the initial public offering proceeds will go toward expanding Coley's early-phase infectious disease program.
You may also be interested in...
Coley Doubles Toll-Like Receptor Patent Estate With Purchase Of 3M Program
$20 million investment also gains the TLR-focused firm a pipeline of small molecule candidates targeting TLR7 and TLR8, as well as a 10,000 compound library.
Coley Doubles Toll-Like Receptor Patent Estate With Purchase Of 3M Program
$20 million investment also gains the TLR-focused firm a pipeline of small molecule candidates targeting TLR7 and TLR8, as well as a 10,000 compound library.
Coley Seeks HCV Partner For Actilon
Firm suspends independent development of the hepatitis C agent in hopes of finding a partner with resources and expertise to share the risk.